Quarterly report pursuant to Section 13 or 15(d)

Comparison of Restated Financial Statements to Financial Statements As Previously Reported (Details 2)

v3.20.4
Comparison of Restated Financial Statements to Financial Statements As Previously Reported (Details 2) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Cash Flows From Operating Activities:        
Net (loss) income $ (5,436,388) $ (10,830) $ (5,653,799) $ 220,765
Adjustments to reconcile net (loss) income to net cash used in operating activities:        
Interest income earned on investments held in Trust Account     (38,438) (948,284)
Stock-based compensation     2,625,000
Amortization of debt discount     252,493
Loss on issuance of convertible promissory notes     1,657,522
Changes in operating assets and liabilities:        
Prepaid income taxes     3,827 (60,357)
Prepaid expenses     (66,855) (38,190)
Other asset     (163,797)
Accounts payable and accrued expenses     571,074 (35,602)
Net cash and restricted cash used in operating activities     (812,973) (943,985)
Cash Flows From Investing Activities:        
Cash withdrawn from Trust Account for redemptions     728,884 69,305,537
Investment of cash in Trust Account     (89,142)
Net cash and restricted cash provided by investing activities     639,742 69,659,351
Cash Flows From Financing Activities:        
Proceeds from promissory note - CannBioRx     9,990 400,000
Repayment of promissory note - CannBioRx     (330,000)
Proceeds from convertible promissory note - related party     33,877
Repayment of convertible promissory note - related party     (62,922) (80,000)
Proceeds from convertible promissory notes     1,750,000
Redemptions of common stock     (728,884) (69,305,537)
Net cash and restricted cash provided by (used in) financing activities     672,061 (68,875,957)
Net Change in Cash and Restricted Cash     498,830  
Cash and Restricted Cash - Beginning of period     546,636  
Cash and Restricted Cash - Ending of period 1,045,466   1,045,466  
Non-cash investing and financing activities:        
Change in value of common stock subject to possible redemption     3,866,200 220,764
Waiver of deferred underwriting fee     4,025,000
Accrual of debt issuance costs     251,566
Initial classification of debt discount in connection with issuance of convertible promissory note     3,316,008
Initial classification of derivative liability in connection with issuance of convertible promissory note     214,188
Original issue discount in connection with issuance of convertible promissory note     194,445
Initial classification of debt discount and issuance of commitment shares, leak-out shares and beneficial conversion feature in connection with convertible promissory note     3,121,563
As Originally Reported [Member]        
Cash Flows From Operating Activities:        
Net (loss) income (2,311,388)   (2,528,799)  
Adjustments to reconcile net (loss) income to net cash used in operating activities:        
Interest income earned on investments held in Trust Account     (38,438)  
Stock-based compensation      
Amortization of debt discount     252,493  
Loss on issuance of convertible promissory notes     1,657,522  
Changes in operating assets and liabilities:        
Prepaid income taxes     3,827  
Prepaid expenses     (66,855)  
Other asset     (163,797)  
Accounts payable and accrued expenses     71,074  
Net cash and restricted cash used in operating activities     (812,973)  
Cash Flows From Investing Activities:        
Cash withdrawn from Trust Account for redemptions     728,884  
Investment of cash in Trust Account     (89,142)  
Net cash and restricted cash provided by investing activities     639,742  
Cash Flows From Financing Activities:        
Proceeds from promissory note - CannBioRx     9,990  
Repayment of promissory note - CannBioRx     (330,000)  
Proceeds from convertible promissory note - related party     33,877  
Repayment of convertible promissory note - related party     (62,922)  
Proceeds from convertible promissory notes     1,750,000  
Redemptions of common stock     (728,884)  
Net cash and restricted cash provided by (used in) financing activities     672,061  
Net Change in Cash and Restricted Cash     498,830  
Cash and Restricted Cash - Beginning of period     546,636  
Cash and Restricted Cash - Ending of period 1,045,466   1,045,466  
Non-cash investing and financing activities:        
Change in value of common stock subject to possible redemption     4,510,285  
Waiver of deferred underwriting fee     4,025,000  
Accrual of debt issuance costs      
Initial classification of debt discount in connection with issuance of convertible promissory note     3,208,527  
Initial classification of derivative liability in connection with issuance of convertible promissory note     214,188  
Original issue discount in connection with issuance of convertible promissory note     194,445  
Initial classification of debt discount and issuance of commitment shares, leak-out shares and beneficial conversion feature in connection with convertible promissory note     3,014,082  
Adjustments [Member]        
Cash Flows From Operating Activities:        
Net (loss) income (3,125,000)   (3,125,000)  
Adjustments to reconcile net (loss) income to net cash used in operating activities:        
Interest income earned on investments held in Trust Account      
Stock-based compensation     2,625,000  
Amortization of debt discount      
Loss on issuance of convertible promissory notes      
Changes in operating assets and liabilities:        
Prepaid income taxes      
Prepaid expenses      
Other asset      
Accounts payable and accrued expenses     500,000  
Net cash and restricted cash used in operating activities      
Cash Flows From Investing Activities:        
Cash withdrawn from Trust Account for redemptions      
Investment of cash in Trust Account      
Net cash and restricted cash provided by investing activities      
Cash Flows From Financing Activities:        
Proceeds from promissory note - CannBioRx      
Repayment of promissory note - CannBioRx      
Proceeds from convertible promissory note - related party      
Repayment of convertible promissory note - related party      
Proceeds from convertible promissory notes      
Redemptions of common stock      
Net cash and restricted cash provided by (used in) financing activities      
Cash and Restricted Cash - Ending of period    
Non-cash investing and financing activities:        
Change in value of common stock subject to possible redemption     (644,085)  
Waiver of deferred underwriting fee      
Accrual of debt issuance costs     251,566  
Initial classification of debt discount in connection with issuance of convertible promissory note     107,481  
Initial classification of derivative liability in connection with issuance of convertible promissory note      
Original issue discount in connection with issuance of convertible promissory note      
Initial classification of debt discount and issuance of commitment shares, leak-out shares and beneficial conversion feature in connection with convertible promissory note     $ 107,481